Business Context and Reporting Period
Company: Personalis, Inc. (PSNL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025 (Second Quarter)
Business Overview: Personalis develops and sells advanced cancer genomic tests and services used by pharmaceutical companies for clinical trials and by physicians for detecting residual or recurrent cancer. The company operates as a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $17,203 | $22,580 | $37,808 | $42,105 |
| Net Loss | $(20,056) | $(12,802) | $(35,806) | $(25,770) |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.24) | $(0.41) | $(0.50) |
| Operating Cash Flow | — | — | $(30,896) | $(31,156) |
| Cash & Short-Term Investments | $173,232 | — | $173,232 | — |
| Total Debt | $2,685 | — | $2,685 | — |
Note: Q2 2024 Operating Cash Flow and Balance Sheet data are not explicitly provided in the text for direct comparison, though YTD figures are available.
Material Changes vs. Prior Period
- Revenue Decline: Q2 2025 revenue decreased 24% year-over-year to $17.2 million. This was primarily driven by a $5.6 million expected decline in revenue from Natera (Enterprise sales) and a $2.1 million decrease in Pharma tests and services.
- Segment Growth: Population sequencing revenue increased 158% year-over-year to $3.3 million, and Clinical diagnostic revenue increased 301% to $0.5 million, partially offsetting the declines in other segments.
- Expense Management: Total costs and expenses remained relatively flat year-over-year (down 1% in Q2). Cost of revenue decreased 14%, while Selling, General, and Administrative (SG&A) expenses increased 18% due to expanded marketing programs for the NeXT Personal Dx test.
- Net Loss Increase: Net loss widened to $20.1 million in Q2 2025 from $12.8 million in Q2 2024. The prior year period included a $3.0 million non-cash gain from the remeasurement of Tempus warrants, which was absent in the current period.
- Liquidity: Cash and cash equivalents decreased from $91.4 million at year-end 2024 to $53.4 million at June 30, 2025, while short-term investments increased to $119.9 million. Total liquidity (cash + investments) stands at $173.2 million.
Guidance, Outlook, and Risks
- Commercialization Strategy: The company is accelerating clinical adoption, delivering 3,478 clinical tests in Q2 2025 (a 59% sequential increase). A key strategic move is the expanded partnership with Tempus AI, Inc., which now includes colorectal cancer as a new indication and extends the agreement term through November 2029.
- Customer Concentration: Revenue remains highly concentrated. For the six months ended June 30, 2025, the top five customers accounted for 72% of revenue. Key customers include ModernaTX (28%), VA MVP (20%), and Natera (13%). The company does not expect a long-term commercial relationship with Natera beyond 2025.
- Reimbursement: As of June 30, 2025, the company has not received Medicare coverage reimbursement for its NeXT Personal Dx test, though it has received coverage for NeXT Dx. Reimbursement challenges remain a significant risk to the clinical diagnostic business model.
- Liquidity Outlook: Management believes current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months. The company maintains an At-the-Market (ATM) facility to raise up to $50.0 million if needed.
- Risks: Key risks include the potential loss of major customers (Natera, VA MVP), failure to secure Medicare reimbursement, reliance on sole suppliers (e.g., Illumina), and the need for additional capital if revenue growth does not offset operating expenses.
Investor Verification Checklist
- Natera Contract Status: Verify the timeline and financial impact of the winding down of the Natera relationship, which accounted for 38% of revenue in the prior year period but only 13% in the current period.
- Medicare Reimbursement: Monitor progress on Medicare coverage for the NeXT Personal Dx test, which is critical for the scalability of the clinical diagnostic segment.
- Tempus Partnership Execution: Assess the revenue contribution from the expanded Tempus agreement, specifically regarding the new colorectal cancer indication and the $6.0 million market development fee structure.
- Capital Runway: Review the burn rate relative to the $173.2 million liquidity position to confirm the 12-month runway assertion, especially given the continued net losses.
- Customer Diversification: Evaluate the company's ability to replace revenue from Natera and mitigate concentration risk with Moderna and VA MVP.